Oncogenic functions and therapeutic targeting of EphA2 in cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• EphA2 receptor tyrosine kinase has been extensively researched for over 25 years.
• It is recognized as a significant molecular target for cancer treatment.
• Preclinical validation supports its role in various cancers.

Purpose of the Study:

• To review preclinical evidence of EphA2's oncogenic role in breast cancer, lung cancer, glioblastoma, and melanoma.
• To delineate the distinct roles of canonical and noncanonical EphA2 signaling in different cancer types.
• To summarize clinical trial data on EphA2-targeting therapies.

Main Methods:

• Review of preclinical studies (molecular, genetic, biochemical, pharmacological).
• Analysis of drug targeting strategies including small molecules, antibodies, and peptide-drug conjugates.
• Examination of immunotherapeutic approaches against EphA2.

Main Results:

• EphA2 plays an oncogenic role in breast cancer, lung cancer, glioblastoma, and melanoma.
• Canonical and noncanonical EphA2 signaling pathways exhibit varied functions across different cancers.
• Various therapeutic strategies, including dasatinib, are being investigated for EphA2 targeting.

Conclusions:

• Targeting EphA2 presents a promising strategy for cancer treatment.
• Diverse therapeutic modalities are under investigation, including immunotherapies.
• Clinical translation of EphA2-targeted therapies faces both promise and challenges.